Background and Purpose-Intraluminal thrombus (ILT) is an uncommon finding among patients with ischemic stroke. We report clinical-imaging manifestations, treatment offered, and outcome among patients with ischemic stroke/transient ischemic attack and ILT in their cervico-cephalic arteries. Methods-Sixty-one of 3750 consecutive patients with acute ischemic stroke/transient ischemic attack (within 24 hours of onset) and ILT on initial arch-to-vertex computed tomography angiography from April 2015 through September 2017 constituted the prospective study cohort. Functional outcome was assessed using the modified Rankin Scale score with functional independence at discharge defined as modified Rankin Scale score ≤2. Results-Prevalence of ILT on computed tomography angiography was 1.6% (95% CI, 1.2%-2.1%). Median age was 67 years (interquartile range, 56-73), and 40 subjects (65%) were male. The initial clinical presentation included transient ischemic attack in 12 (20%) and stroke in 49 patients (80%); most strokes (76%) were mild (National Institutes of Health Stroke Scale ≤5). The most common ILT location was cervical carotid or vertebral artery (n=48 [79%]) followed by intracranial (n=11 [18%]) and tandem lesions (n=2 [3%]). The most common initial treatment strategy was combination antithrombotics (heparin with single antiplatelet agent) among 57 patients (93%). Follow-up computed tomography angiography (n=59), after a median 6 days (interquartile range 4-10 days), revealed thrombus resolution in 44 patients (75% [completely in 27%]). Twenty four of 30 patients (80%) with >50% residual carotid stenosis underwent carotid revascularization (endarterectomy in 15 and stenting in 9 patients) without peri-procedural complications a median of 9 days after symptom onset. In-hospital stroke recurrence occurred in 4 patients (6.6%). Functional independence was achieved in 46 patients (75%) at discharge. Conclusions-Patients presenting with acute stroke/transient ischemic attack with ILT on baseline imaging have a favorable clinical course in hospital with low stroke recurrence, high rate of thrombus resolution, and good functional outcome when treated with combination antithrombotic therapy.
R outine use of arch-to-vertex vascular imaging among patients with ischemic stroke has enabled increased recognition of intraluminal thrombus (ILT) in the extra and intracranial arteries. This phenomenon has also been termed intraluminal clot, 1,2 intraluminal nonocclusive thrombus, 3 free-floating thrombus, 4 and colloquially the doughnut sign. Studies based on catheter angiography reported a prevalence of ILT ranging from 0.4% to 1.5%. 1, 5 More recent studies using computed tomography angiography (CTA) show a prevalence of 3.2% among patients with acute stroke/transient ischemic attack (TIA). 3, 6 Prevalence of ILT is higher in the presence of high-grade carotid stenosis, 7 although ILT is also seen in nonatherosclerotic arteries 2 and in patients without arterial stenosis. 8 The presence of ILT is a therapeutic challenge because of the perceived high risk of stroke recurrence and the lack of empirical evidence to guide appropriate treatment strategies (medical or surgical). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Despite enthusiasm for anticoagulation as a medical treatment strategy in some studies, 1,2,5,9,10 diverse antithrombotic approaches are used. 3, 8 Furthermore, in patients with carotid stenosis who are otherwise candidates for endarterectomy or stenting, the safety of intervention when ILT is present is unknown. Small observational studies 9, 10 and post hoc sub-group analysis from the NASCET
Stroke

February 2019
(North American Symptomatic Carotid Endarterectomy Trial) 11 have reported increased perioperative risk of stroke and death among patients with ILT resulting in uncertainty on the optimal timing for intervention. 10, 12, 13 We report a prospective single-center experience of clinical and imaging manifestations of acute ischemic stroke/TIA associated with ILT, treatment strategies employed, imaging, and clinical outcomes.
Methods
Patient Selection
The Conjoint Health Research Ethics Board of the University of Calgary approved the study, and waiver of consent was obtained for this observational data. All suspected stroke/TIA patients presenting to our center undergo noncontrast CT followed by multiphase CTA. Consecutive patients presenting with acute ischemic stroke/TIA (within 24 hours of symptom onset) from April 2015 to September 2017 were prospectively enrolled in the study if they had ILT identified by a neuroradiologist on initial arch-to-vertex CTA. A second expert neuroradiologist (Dr Eesa) then confirmed the findings. ILT was identified on CTA as a filling defect within the arterial lumen completely surrounded by contrast on at least 2 contiguous source images in the plane transverse to the target artery axis (axial images for extracranial and axial or sagittal/coronal images for intracranial artery). Patients with proximally occluded arterial segment and ILT at the distal end of the occlusion projecting into the arterial lumen were also included. The data that support the findings of this study are available from the corresponding author on reasonable request.
Clinical Data
We collected details on demographic features, clinical variables, including National Institutes of Health Stroke Scale (NIHSS), and vascular risk factors. Results of hematologic and biochemical tests were reviewed. Thrombophilia workup was performed in select cases where it was suspected based on relevant clinical history or in young patients with undetermined cause. Neurological deterioration after admission was defined as an increase of ≥4 points in the NIHSS from baseline to 24 hours. Stroke recurrence (new deficits) was recorded by the treating physician and confirmed on imaging (CT or magnetic resonance imaging brain). Antithrombotic regimen at baseline, immediately after ILT ascertainment, and after admission (maintenance) was recorded. Time to carotid endarterectomy (CEA) or stenting, if performed, was noted. Any adverse events (intracranial or peripheral bleeding or otherwise) were recorded. Functional outcome was assessed using the modified Rankin Scale score at discharge.
Image Acquisition
All patients had noncontrast CT head followed by multiphase CTA acquired on a multislice CT scanner (GE Medical Systems or Siemens). CTA acquisitions were obtained after a single bolus intravenous contrast injection of 70 to 90 mL of iohexol (Omnipaque 350, GE Healthcare) in antecubital vein at a rate of 5 mL/s. Imaging was auto triggered by the appearance of contrast material in the ascending aorta and scanning performed from the aortic arch to the vertex with 0.625 mm slice thickness. All acquisitions were followed by generation of multiplanar volume reformatted images of 3.0 mm slice thickness in axial, sagittal, and coronal planes.
Image Analysis
A neuroradiologist (Dr Eesa) reviewed all source and reformatted images of patients with potential ILT based on initial radiology report and assessment by treating stroke neurologist. Presence of infarct was assessed on initial noncontrast CT and classified into small, moderate, and large. Large infarcts were defined as involving ≥50% of large intracranial artery territory producing mass effect on adjacent ventricle with or without midline shift. Large intracranial arteries of interest were anterior, middle, and posterior cerebral arteries in supratentorial region and anterior inferior, posterior inferior, and superior cerebellar arteries in infratentorial region. Moderate size infarct involved 25% to 50% of the arterial territory with no significant mass effect, and others infarcts were classified as small (ie, <25% of territory). Any hemorrhagic transformation was recorded and considered symptomatic if associated with neurological deterioration (defined as worsening of NIHSS by 4 points). Severity of stenosis at the site of maximal luminal narrowing of symptomatic artery was rated according to NASCET criteria 14 for extracranial arterial segments and Warfarin-Aspirin Symptomatic Intracranial Disease criteria 15 for intracranial arterial segments. Follow-up CTA was used to compare ILT to that seen on baseline CTA (Figure 1 ) and to grade thrombus resolution using a 3-point scale as (1) unchanged, (2) partially resolved, or (3) completely resolved. Partially resolved thrombus was further divided into <50% versus 50% to 99% resolution. Thrombus resolution was visually assessed using a combination of improvement of lumen diameter and reduction in thrombus bulk. Timing of follow-up CTA was left to the discretion of treating clinician and generally performed 3 to 5 days after the treatment initiation.
Statistical Analysis
Data are reported using standard descriptive statistics. Frequency (percentage) are presented for categorical or ordinal variables. Initial stroke severity was classified into mild, moderate, and severe based on initial NIHSS of 0 to 5, 6 to 15, and >16, respectively. Normality of data distribution was assessed using the Shapiro-Wilk test. Continuous variables are presented as mean (SD) for normally distributed data or median (interquartile range, IQR) for nonparametric data. Student t test, Mann-Whitney U test, and the Fisher exact test were used as appropriate. Logistic regression was used to build a multivariable model testing association between baseline clinical and imaging variables and ILT resolution (any versus no resolution) and also stenosis improvement (from > 50 to <50%). All variables with P<0.20 in univariate analysis were included in the multivariable logistic regression model. A final parsimonious model was arrived using backward elimination. All analyses were performed using Stata software (version 13, StataCorp, College Station, TX).
Results
Baseline Patient Characteristics and Clinical Presentation
Sixty-one patients with ILT were included for analysis from April 01, 2015 to September 31, 2017. There were 3750 CTA studies performed during this period for suspected stroke/TIA; the CTA prevalence of ILT was 1.6% (95% CI, 1.2%-2.1%). The median age of included patients was 67 years (IQR, 56-73), and 40 patients (65.6%) were men. Hypertension (47.5%), smoking (44.3%), and dyslipidemia (41%) were the most common vascular risk factors (Table 1) . Two patients (3.2%) had active malignancy (one had ovarian carcinoma, and another patient had small cell lung carcinoma). Initial clinical presentation included TIA in 12 patients (19.7%) and stroke in 49 patients (80.3%). Median baseline NIHSS was 2 (IQR, 1-4). Initial stroke severity was mild in 37 out of 49 patients (75.5%). Two patients (3.2%) received intravenous alteplase. Thirteen patients (21.3%) were on aspirin at admission versus 5 (8.2%) on anticoagulants (apixaban [1] , warfarin [3] , tinzaparin [1] ).
Baseline Imaging Features
Distribution of ILT within the arterial tree is summarized in Table 1 The most common cause underlying ILT was atherosclerotic disease of the affected vessel (seen in 50/61 patients [82.0%]) manifested by either ulcerated plaque with or without luminal stenosis or plaque with >50% stenosis. Ulcerated plaque was unmasked on follow-up imaging in 4 patients (6.6%). Median percentage arterial stenosis was 68% (IQR, 54-74); 51 patients (83.6%) had ≥50% arterial stenosis, whereas 5 patients (8.2%) had occluded proximal segments (3 patients with carotid and 2 patients with VA involvement). Other causes included arterial dissection in 4 cases (6.6%) and cardioembolism in 1 patient (1.6%). Two patients (3.2%) had suspected hypercoagulable state secondary to active cancer. In the remaining 4 subjects (6.6%), a cause of ILT remained unknown. Patients with nonatherosclerotic cause for ILT were significantly younger than patients with atherosclerotic cause (mean±SD age of 50.7±14.0 versus 67.5±11.5 years; P<0.001) as were patients with unknown cause (mean age, 45±17.3 versus 64.7±13.0 years; P=0.006).
Initial noncontrast CT revealed no infarct in 31 (50.8%) patients (Table 1) . Infarcts associated with ILT were primarily arteroembolic ( Figure III in the online-only Data Supplement) in nature (97.7%). One patient had an infarct in the anterior/ posterior external watershed region which was interpreted to be either arteroembolism to the distal branches of the intracranial circulation or because of a low flow state (hemodynamic). Most infarcts were small (n=23/30 [76.7%]). Only 1 patient (1.6%) had hemorrhagic transformation of infarct at baseline.
Initial Treatment Strategies and In-Hospital Course
The initial treatment strategy was primarily a combination antithrombotic regimen of intravenous unfractionated heparin and 1 antiplatelet agent (either aspirin or clopidogrel) in 93.4% patients (n=57). Weight-based nomogram was used to calculate heparin dose with target activated partial thromboplastin time between 1.5 and 2.0; no initial heparin bolus was given. Two patients (3.3%) were initially managed only on intravenous heparin (one had cardioembolic stroke related to atrial fibrillation and was discharged on warfarin, whereas another patient received intravenous heparin until CEA and discharged on aspirin). Two patients (3.3%) received antiplatelet agents (one patient received aspirin monotherapy and other dual therapy with aspirin and clopidogrel) throughout Table 2 shows the follow-up clinical and imaging outcomes. Four patients (6.6%) had stroke/TIA recurrence during their hospital stay. Two patients had stroke recurrence on day 3 of admission; one patient with intracranial VA-ILT was on aspirin/heparin therapy, whereas another patient with extracranial ICA-ILT was on aspirin monotherapy at the time of recurrence. In both patients, clopidogrel was added with no subsequent stroke/TIA recurrences. Two patients with extracranial ICA-ILT had a TIA on aspirin+heparin (day 5) and aspirin-clopidogrel dual antiplatelet therapy (day 11), respectively. Clopidogrel was added in the former patient, whereas the second patient was monitored with transcranial doppler with no further emboli and, therefore, remained on dual antiplatelet therapy. Both patients remained symptom-free, subsequently. Fifty-nine patients (96.7%) had follow-up imaging a median 6 days (IQR, 4-10 days) after baseline imaging. Follow-up parenchymal imaging (magnetic resonance imaging in 58/59 patients) revealed asymptomatic hemorrhagic transformation of infarct in 11.9% patients (7/59). ILT remained unchanged on follow-up CTA in 25.4% patient (15/59), partially resolved in 47.5% (28/59), and resolved completely in 27.1% patients (16/59). Thus 75% had at least some ILT resolution. Median residual stenosis in the symptomatic artery was 61% (IQR, 38-68), and stenosis over 50% was noted in 71.2% (42/59). In patients with carotid ILT (n=40), median residual stenosis was 62% (IQR, 50-61), and 75% (30/40) had carotid stenosis ≥50%. On follow-up CTA, 9 of all (14.8%) and 5 of 40 carotid stenosis patients (12.5%) had reduction in stenosis from >50% to under 50%. Five patients (8.2%) who had occluded arteries on initial imaging Congestive heart failure 1 (1. Of the total cohort, 75.4% patients (n=46) were independent and discharged home; 23% (n=14) had modified Rankin Scale score 3, whereas 1.6% (n=1) had modified Rankin Scale score 4 before transfer to rehabilitation services. No patient died in the present cohort. Median length of hospital stay was 8 days (IQR, 6-13; range, 2-74 days).
Follow-Up Treatment and Outcome
Predictors of Thrombus Resolution and Stenosis Reduction
Patients who had any (partial or complete) resolution of ILT differed in several characteristics from patients without ILT resolution in univariate analysis (Table 3) . However, time to therapeutic anticoagulation (first 2 activated partial thromboplastin time between 1.5 and 2.0) was distributed similarly (P=1.00) and was achieved within 24 hours among 86.7% of no ILT resolution versus 86.4% of ILT resolution group. Duration of heparin treatment was similar between these 2 groups (median 7 versus 6 days in no ILT resolution versus any resolution group; P=0.33). On multivariable analysis (Table 3) , presence of ILT in extracranial location was associated with higher odds of resolution of ILT on follow-up CTA (odds ratio, 8.3; 95% CI, 1.7-42.1; P=0.01), whereas prior use of anticoagulants reduced the odds of thrombus resolution (odds ratio, 0.1; 95% CI, 0.0-0.9 P=0.04). Patients who had stenosis reduction from >50% to <50% tended to be younger, more often had history of alcohol, use and had longer time to follow-up CTA in multivariable analysis (Table II in 
Discussion
This study shows that the prevalence of ILT among patients with acute stroke/TIA is low at 1.6% (95% CI, 1.2%-2.1%). Two-thirds of all ILTs were seen in the cervical carotid arteries, and 1 out of 10 were found in the VAs. One of every 5 ILTs was intracranial. Coexisting atherosclerosis was the most common cause. Three-quarters of all ILTs resolved at least partially (a quarter of all ILTs resolved completely) within a week on average with combination antithrombotic medications (heparin with 1 antiplatelet agent). Neurological deterioration 
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after admission was uncommon (1.6% of patients) when patients were treated with combination antithrombotics. One in 7 patients with >50% stenosis of carotid artery at baseline (potential candidates for CEA or CAS) had <50% stenosis of the same artery on follow-up imaging. The prevalence and location of ILT varies among prior studies because of differences in the population selected, vascular imaging modality used, and criteria used to define ILT. 1, 3, 5, 6, 16, 17 A previous study from our center reported carotid ILT in 3.1% of patients with acute stroke/TIA. 6 In another retrospective study, the prevalence of intracranial nonocclusive thrombus was 2.7%. 3 In contrast, ILT in VAs is rarely reported. 10 This study provides more precise estimates of the hospital-based prevalence of ILTs on baseline CTA in this prospective study. In addition, the study also shows that atherosclerotic disease (ulcerated or complex plaque) seems to be the most common cause of ILT (82% of our population) in elderly patients and generally occurs in the presence of conventional vascular risk factors, whereas vessel dissection could cause ILT in younger patients. 2, 10 Patients with no identifiable cause should be investigated for underlying hypercoagulable state and malignancy (found in 2 of our patients). 1, 2, 10, 18 Cardioembolism may cause or coexist with other potential causes but is not a common cause for ILTs.
The natural history of ILT is variable; potential outcomes include progression to occlusion, distal embolization of fragments or the entire clot, stabilization, or disappearance.
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Few studies have assessed utility of different therapeutic approaches to treat ILT, although the presence of ILT is thought to confer increased risk of recurrent stroke while in hospital. Transcranial Doppler studies have shown an increased risk of distal embolization in patients with ILT. 20 Interestingly, the risk of recurrent stroke in our study was low (≈1 in 20 patients); this low risk could be because most of our patients were treated with a combination antithrombotic regimen (heparin and 1 antiplatelet agent). This treatment regimen was safe with no patient having any clinically relevant bleeding while on the treatment regimen. Moreover, three-quarters of our patients had either partial or complete resolution of thrombus and improvement in lumen caliber on this treatment regimen. Of note, prior use of anticoagulants was associated with lower odds of thrombus resolution in this study. This could be because these patients had thrombus formation in a milieu that was refractory to heparin/anticoagulants.
Patients who were eligible for carotid revascularization were safely treated after initial medical management. About one-fifth of the patients had the procedure performed in the presence of observable thrombus (33.3% CAS and 13.3% CEA). No patient had peri or postprocedural stroke/death. These data support the safety of early (first 2 weeks) carotid revascularization in patients with ILT offered combination antithrombotic (heparin and 1 antiplatelet agent) on admission. On follow-up CTA, about 1 in 7 patients had reduction in stenosis from >50% to under 50%. The presence of ILTs could, therefore, result in over-estimation of underlying stenosis. Initial medical therapy with follow-up imaging may, therefore, help to identify exact degree of stenosis allowing these patients to select for carotid intervention. Moreover, the likelihood of patients with >50% stenosis on baseline imaging and <50% stenosis on follow-up imaging increases with time while still in hospital. Evidence on whether these patients would benefit from CEA/CAS when stenosis is <50% on follow-up imaging is as yet unknown.
Key strengths of our study are the prospective design, consecutive patient enrollment, uniform imaging protocol at baseline and follow-up, and completeness of clinical and neuroimaging data at baseline and on follow-up. However, a few limitations are worth noting. First, because only symptomatic patients were imaged, the prevalence of ILTs is likely an underestimate. Second, this study was not designed to evaluate the relative efficacy of combination versus single antithrombotic regimens, nor the safe timing of revascularization procedures in the setting of ILT; therefore, these findings must be interpreted with caution. Third, patients were not followed up beyond discharge, making it difficult to ascertain out-of-hospital stroke recurrence or clinical outcomes. Fourth, analysis on predictor of stenosis reduction was underpowered because of small number of patients in stenosis reduction group, thus needs validation. Finally, advanced imaging technology could help in delineating imaging characteristics, such as craniocaudal extent of ILT that were not studied in this analysis. Similarly, use of advanced plaque imaging might help to identify small thrombi on ruptured plaques, likely missed in the present study because of strict inclusion criteria (required clot to be seen on 2 continuous source images) and their clinical significance. 
Conclusions
In conclusion, ILT occurs in a wide range of extra and intracranial arterial locations and in the presence of vascular risk factors. Prognosis is generally good with favorable clinical and imaging outcomes. Initial medical management with combination antithrombotic (heparin and 1 antiplatelet agent) is safe in a majority of patients. Early carotid revascularization could be safely performed in eligible patients. Future studies should compare the efficacy and safety of different antithrombotic regimens including dual antiplatelet or oral anticoagulation in such patients, including how these treatment regimens may affect utilization and outcomes in patients offered CEA or CAS. It would also be interesting to investigate if the ILTs seen at later time windows (onset to CTA >24 hours) and thus increasingly organized thrombus structure would show similar clinical behavior and response to combination antithrombotic therapy.
